Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Practice Point
  • Published:

Is fulvestrant more effective than tamoxifen for treating ER-positive breast cancer in postmenopausal women?

Nature Clinical Practice Oncology volume 1, pages 20–21 (2004)Cite this article

boxed-textHowell A et al. (2004) Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized trial. J Clin Oncol 22: 1605–1613

Background

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Howell A et al. (2002) Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. J Clin Oncol 20: 3396–3403

    Article  CAS  Google Scholar 

  2. Osborne CK et al. (2002) Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant with anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American Trial. J Clin Oncol 20: 3386–3395

    Article  CAS  Google Scholar 

  3. Mouridsen H et al. (2003) Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group. J Clin Oncol 21: 2101–2109

    Article  CAS  Google Scholar 

  4. Nabholtz JM et al. (2003) Anastrozole (Arimidex) versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: survival analysis and updated safety results. Eur J Cancer 39: 1684–1689

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The synopsis was written by David Bruce, Associate Editor, Nature Clinical Practice.

Author information

Authors and Affiliations

  1. Professor of Medical Oncology at the All India Institute of Medical Sciences, New Delhi, India

    Vinod Raina

Authors
  1. Vinod Raina
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Vinod Raina.

Ethics declarations

Competing interests

The author declares no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Raina, V. Is fulvestrant more effective than tamoxifen for treating ER-positive breast cancer in postmenopausal women?. Nat Rev Clin Oncol 1, 20–21 (2004). https://doi.org/10.1038/ncponc0010

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncponc0010

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing